A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...

For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

The incretin-based therapies reduced mortality and hospitalization risk in individuals with heart failure with preserved ejection fraction.